Related Experiment Video
Updated: May 30, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic medication for cardioembolic stroke prevention
M Àngels Font1, Jerzy Krupinski, Adrià Arboix
1Institut d'Investigacions Biomèdiques de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Stroke Research and Treatment
|August 9, 2011
Summary
Cardioembolic stroke, often caused by atrial fibrillation, is severe and recurrent. New anticoagulants offer potential benefits but require further study due to safety concerns like bleeding.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Cardioembolic stroke accounts for 20% of ischemic strokes, with nonvalvular atrial fibrillation being the primary cause.
- Atrial fibrillation prevalence is increasing globally, particularly with an aging population.
- Cardioembolic strokes are severe, with high recurrence rates, mortality, and underutilization of preventive anticoagulation.
Purpose of the Study:
- To review the role of anticoagulation in preventing cardioembolic stroke.
- To explore alternative anticoagulation therapies for atrial fibrillation patients.
- To discuss the potential benefits and risks of novel anticoagulants.
Main Methods:
- Literature review of studies on cardioembolic stroke and atrial fibrillation.
- Analysis of current anticoagulation guidelines and practices.
- Evaluation of emerging anticoagulant therapies, including direct oral anticoagulants.
Main Results:
- Continuous oral anticoagulation is underprescribed in high-risk atrial fibrillation patients.
- Immediate anticoagulation is not recommended for acute cardioembolic stroke.
- New anticoagulants (e.g., factor Xa inhibitors, direct thrombin inhibitors) show promise with fixed dosing and oral administration.
Conclusions:
- Novel anticoagulants offer advantages over traditional therapies but require further investigation.
- Potential risks include hepatotoxicity, bleeding, and acute coronary events.
- Post-marketing surveillance and additional trials are crucial for evaluating safety and efficacy.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Pulmonary Embolism III: Nursing Management
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...